AlphaVax Signs Licensing Deal with Novartis
Novartis has agreed to license a Phase I vaccine for cytomegalovirus infections from AlphaVax Inc., a Durham, N.C.-based developer of vaccine products for infectious diseases, biodefense and cancer. The deal includes a $20 million upfront payment and the possibility of future equity investments based on clinical milestones. AlphaVax has raised around $41 million in private equity funding from undisclosed investors.
30 December 2008•2 mins read
